Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE:BSX) failed to manage Boston Scientific in an acceptable manner,
Blackstone Life Sciences ("BXLS") today announced a $455 million collaboration with Boston Scientific Corporation (NYSE:BSX) to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular
Both post-implant monotherapies in the trial achieved non-inferiority compared to dual anti-platelet therapy (DAPT) supporting the potential to simplify post-procedure drug regimensMARLBOROUGH, Mass. and SAN DIEGO, Nov.
ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.
MARLBOROUGH, Mass., Oct. 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operational1 and
Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE:BSX) failed to manage Boston Scientific in an acceptable manner,
New operating structure designed to increase efficiency and support continued growthMARLBOROUGH, Mass., Oct. 7, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced the appointment of Joseph M.
Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan
MARLBOROUGH, Mass., Aug. 10, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026. Mike Mahoney, chairman
ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.
MARLBOROUGH, Mass., July 29, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery diseaseMARLBOROUGH, Mass. and PARIS, May 19,
MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National
Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloyMARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation
